Showing results (181-190 of 196) with videos related to
Sort By:
Pageof 20
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 26, 2006
Refractory ascites after liver transplantation: an analysis of 1058 liver transplant patients at a single centerS Nishida, J J Gaynor, N Nakamura, et al.American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 12, 2012
Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trialM F Abdelmalek, A Humar, F Stickel, et al.The Annals of Pharmacotherapy|October 28, 2004
Tenofovir therapy for lamivudine resistance following liver transplantationGuy W Neff, Jose Nery, Daryl Ty Lau, et al.Plos Genetics|October 3, 2012
Variation in genes related to cochlear biology is strongly associated with adult-onset deafness in border colliesJennifer S Yokoyama, Ernest T Lam, Alison L Ruhe, et al.The New England Journal of Medicine|June 7, 2024
A Phase 2 Randomized Trial of Survodutide in MASH and FibrosisArun J Sanyal, Pierre Bedossa, Mandy Fraessdorf, et al.Nature Medicine|June 7, 2026
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trialLee M Kaplan, Elena Startseva, Carel W le Roux, et al.Plos One|September 24, 2010
An ADAMTSL2 founder mutation causes Musladin-Lueke Syndrome, a heritable disorder of beagle dogs, featuring stiff skin and joint contracturesHannah L Bader, Alison L Ruhe, Lauren W Wang, et al.Lancet (London, England)|August 16, 2025
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trialMazen Noureddin, Juan P Frias, Guy W Neff, et al.Journal of Hepatology|June 10, 2024
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosisEric J Lawitz, Mandy Fraessdorf, Guy W Neff, et al.The New England Journal of Medicine|May 9, 2025
Efruxifermin in Compensated Liver Cirrhosis Caused by MASHMazen Noureddin, Mary E Rinella, Naga P Chalasani, et al.Pageof 20